Tetraphase Pharmaceuticals (TTPH) PT Raised to $51 at Wedbush

Tetraphase Pharmaceuticals (TTPH) PT Raised to $48 at BMO Capital

BMO Capital analyst Jim Birchenough boosted his price target on Outperform-rated Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $48 from $33 following positive top-line results from the phase 3 IGNITE 1 trial of eravacycline in complicated intra-abdominal infections (cIAI).

Birchenough commented, "We are reiterating our Outperform rating on TTPH and... More

Tetraphase Pharmaceuticals (TTPH) PT Raised to $40 at Cantor Fitzgerald

Cantor Fitzgerald analyst Daniel Brims reiterated a Buy rating and boosted his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $40.00 (from $26.00) after the IGNITE1 study in cIAI met the primary endpoint.

Brims commented, "The phase 3 IGNITE1 study enrolled 541 patients to test the non-inferiority of eravacycline against the standard of care,... More

Tetraphase Pharmaceuticals (TTPH) PT Raised to $45 at Guggenheim

Guggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $45.00 (from $33.00) following positive top-line IGNITE 1 results.

Chen commented, "We are increasing our price target for TTPH from $33 to $45 following positive top-line eravacycline... More

Tetraphase Pharmaceuticals (TTPH) Target Raised to $46 at Needham & Company

Needham & Company analyst Alan Carr reiterated a Buy rating and boosted his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $46.00 (from $28.00) following positive Phase 3 Eravacycline results in cIAI.

Tetraphase announced positive results yesterday from its Phase 3 trial of IV eravacycline in complicated Intra-abdominal... More

Tetraphase Pharmaceuticals (TTPH) PT Lifted to $41 at Baird on Bullish IGNITE-1 Data

Baird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) price target of $41.00 (from $28.00) following positive IGNITE-1 data.

Skorney commented, "We didn't see any surprises in the top-line IGNITE-1 dataset with eravacycline achieving statistical... More

Tetraphase Pharma (TTPH) Announces Positive Phase 3 IGNITE 1 Results

Tetraphase Pharma (Nasdaq: TTPH) announced positive top-line results from IGNITE 1, the Companys Phase 3 clinical trial of eravacycline for the treatment of complicated intra-abdominal infection (cIAI) compared to ertapenem. In the trial, eravacycline met the primary endpoint of statistical non-inferiority of clinical response at the test-of-cure (TOC) visit, under the guidance... More